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Abstract The sulphonylureas glibenclamide and tolbutamide in- 
hibited carnitine acyltransferase activities in rat liver micro- 
somes. Glibenclamide was a more potent inhibitor than tolbu- 
tamide. The effect of tolbutamide on the malonyl-CoA-inhibitable 
transferase was influenced by the phospholipid/detergent viron- 
ment whereas the effect of glibenclamide was not. Glibenclamide 
was a more potent inhibitor of the malonyl-CoA-inhibitable trans- 
ferase than of the malonyl-CoA-insensitive enzyme. The ext nt 
of inhibition of the malonyl-CoA-inhibitable transferase by tolbu- 
tamide was similar to its effect on VLDL triacylglycerol secretion 
as reported by Wiggins and Gibbons [Biochem. J. 284 (1992) 
457-462] possibly supporting the suggestion that microsomal car- 
nitine acyltransferases are involved in VLDL triacylglyceroi as- 
sembly/secretion. 
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Wiggins and Gibbons [8] have shown that the sulphonylurea 
drug tolbutamide is able to suppress VLDL triacylglycerol se- 
cretion by hepatocytes. Tolbutamide appeared to have two 
actions. One was to decrease hepatocyte lipolysis. The other 
was an independent effect on subsequent VLDL assembly and/ 
or secretion. Since some sulphonylurea drugs had previously 
been shown to inhibit carnitine acyltransferase activities from 
mitochondria [10] we decided to investigate whether tolbu- 
tamide and glibenclamide (glyburide) could inhibit one or other 
of the microsomal CATs. 
2. Materials and methods 
2.1. Chemicals 
1- {4-[2-(5-chloro-2-methoxybenzamido)ethyl]benzene-sulphonyl}-3- 
cyclohexylurea (glibenclamide), 1-butyl-3-p-tolylsulphonylurea (tolbu- 
tamide) and N,N-dimethylformamide were from Sigma. Dimethyl- 
sulphoxide was from Fisons. Animals and all other reagents were as 
described previously [5], 
1. Introduction 
Carnitine acyltransferases that catalyze the interconversion 
of medium- or long-chain fatty acyl-CoA esters with the corre- 
sponding acylcarnitines have been described in many mammal- 
ian tissues. In liver carnitine acyltransferase (CAT) activities 
have been reported in mitochondria, in peroxisomes, in micro- 
somes and in nuclei [14]. Recently we [5] and others [6] have 
provided evidence that rat liver microsomes contain two dis- 
tinct CATs. One of these activities is membrane-bound, ap- 
pears to be oriented towards the cytosolic compartment and 
can be inhibited by physiological concentrations of malonyl- 
CoA. The other CAT activity is latent in 'intact' microsomes, 
is insensitive to malonyl-CoA and has a lumenal location. The 
physiological function of these microsomal CATs is not yet 
clearly established. It has been suggested [5] that they might be 
part of a system that enables transport of fatty acyl units be- 
tween the cytosol and the lumen of the endoplasmic reticulum 
(this presupposes the existence also of a microsomal car- 
nitine:acylcarnitine translocase). Studies with primary cultures 
of rat hepatocytes [7 9] have led to the conclusion that fatty 
acids incorporated into secreted VLDL triacylglycerols are 
largely derived from lipolysis of a hepatic ytoplasmic pool of 
triacylglycerol. As a corollary to this it would seem likely that 
the synthesis of these discrete pools of VLDL and cytoplasmic 
store triacylglycerols should be spatially separated and we have 
speculated [5] that provision of fatty acyl units to the lumen of 
the secretory compartment may be part of this separation. 
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2.2. Isolation ofmicrosomal membranes 
Rough microsomes were isolated from livers of fed male Sprague 
Dawley rats (200-250 g) by sucrose density-gradient centrifugation [11]. 
Membrane residues depleted of malonyl-CoA-insensitive CAT were 
obtained by freeze/thawing and recentrifugation f membranes a de- 
scribed in [5]. 
2.3. Carnitine acyltransferases (CATs) 
Malonyl-CoA-sensitive CAT was solubilized with sodium deoxycho- 
late and partially purified by Superdex 200 gel-filtration [5]. Malonyl- 
CoA-insensitive CAT was released from intact microsomes by freeze- 
thawing/ultracentrifugation [5] a d partially purified by ion-exchange 
chromatography onResource Q [5]. 
2.4. Assay of carnitine acyltransferase 
CAT activity was assayed spectrophotometrically t 25°C in the 
direction of acylcarnitine formation. Unless stated otherwise assays 
(1 ml) contained: 50 mM KH2PO4/K2HPO4 buffer (pH 7.5), 1.3 mg/ml 
fatty acid-poor bovine serum albumin, 125 pM 4,4'-dithiodipyridine, 
100/IM decanoyl-CoA, 20-100 pg enzyme protein and the appropriate 
inhibitor. After 5 rain incubation at 25°C assays were initiated by the 
addition of the stated concentration f L-carnitine. Rates were corrected 
for carnitine-independent CoASH release. Activity was calculated 
using E324 = 19.4 mM ~.cm ~. Olibenclamide was introduced into assays 
in 5 ~1 of dimethylformamide. Tolbutamide was introduced in 10 pl of 
dimethylsulphoxide. Controls (i.e. no inhibitor present) also received 
dimethylformamide or dimethylsulphoxide as appropriate. 
2.5. Reconstitution of malonyl-CoA-sensitive CAT 
Malonyl-CoA-sensitive CAT from the Superdex 200 column was 
reconstituted into L-c~-lecithin l posomes exactly as described in [5]. 
2.6. Analysis ofdata 
K~ and Vm~ Xvalues were determined using a computer programme 
in which starting values of Kin and Vmax were obtained by linear egres- 
sion fitting to a Hanes-Woolf plot and these values were then used to 
seed a non-linear regression analysis which fitted the data to the best 
fit hyperbola [12,13]. Statistically significance was determined by Stu- 
dent's t-test for paired samples. 
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3. Results and discussion 
Fig. 1 shows that both tolbutamide and glibenclamide inhib- 
ited the malonyl-CoA-sensitive CAT activity. With the enzyme 
in situ in membrane residues that had been frozen/thawed in
order to deplete them of the malonyl-CoA-insensitive CAT 
approx. 2.1 mM tolbutamide caused 50% inhibition in assays 
with 100/IM carnitine (a concentration of this substrate which 
is not dissimilar from the concentration of free carnitine in rat 
liver [14,15]). Increasing the carnitine concentration to 2 mM 
lessened substantially the inhibitory effect of tolbutamide. With 
the concentration of the fatty acyl-CoA substrate decanoyl- 
CoA fixed at 100/IM (which is sufficient to saturate the en- 
zyme) tolbutamide produced mixed inhibition kinetics with re- 
spect to carnitine (Table 1). We also examined the effect of 
tolbutamide on partially purified preparations of the malonyl- 
CoA-sensitive CAT. In detergent-solubilized form the CAT 
was less sensitive to inhibition by tolbutamide whereas reconsti- 
tution of the enzyme into lecithin liposomes more than restored 
'normal' sensitivity to tolbutamide. In this respect it is notewor- 
thy that sensitivity of this CAT to inhibition by malonyl-CoA 
is similarly affected by the detergent/phospholipid environment 
[5]. Fig. 1 also shows that approx. 30 pM glibenclamide caused 
50% inhibition of the malonyl-CoA-sensitive CAT. By contrast 
with tolbutamide the inhibitory potency of glibenclamide was 
unaffected by the detergent/phospholipid environment. Fur- 
thermore variation in the concentration of carnitine caused no 
change in the sensitivity to glibenclamide (Fig. 1) and the effect 
of glibenclamide was clearly non-competitive with respect o 
carnitine (Table 1). The effects of the two drugs on the two 
distinct microsomal CATs were also compared (Fig. 2). Since 
the malonyl-CoA-insensitive enzyme can only be separated 
from the malonyl-CoA-sensitive CAT by solubilization proce- 
dures we decided to make the comparison using solubilized 
preparations of both enzymes. These differed only in that the 
malonyl-CoA-sensitive CAT was obtained from a Superose 200 
gel-filtration i  a buffer containing 5 mM sodium deoxycholate 
whereas the malonyl-CoA-insensitive enzyme was obtained 
from a Resource Q ion-exchange fractionation in the same 
buffer, but containing 1.5 mM sodium cholate. Tolbutamide 
had broadly similar inhibitory effects on both enzymes (Fig. 2) 
Table 1 
Effects of tolbutamide and glibenclamide on kinetic constants of the 
malonyl-CoA-sensitive CAT 
Experiment n Sulphonylurea Vm,~ K,, for L-car- 
no. (relative) nitine (mM) 
1 3 none 105 + 1 047 + 0.13 
1 3 tolbutamide 81 _+ 2 c 1.08 + 0.28 A 
(5 mM) 
2 3 none 105 + 1 050 + 0.06 
2 3 glibenclamide 
(25 ktM) 65 + 4 B 0.53 + 0.10 Ns 
All assays were p rformed with microsomal membrane r sidues which 
had been depleted of the malonyl-CoA-insensitive CAT by freezing/ 
thawing. Throughout [decanoyl-CoA] was fixed at 100 ,uM and L- 
carnitine used at 6-7 different concentrations over the range 0.1 mM 
to 10 mM. Values of Kin and Vma xwere calculated as described in section 
2. The value of Vm, x in every case was set relative to the activity 
observed with 10 mM L-carnitine in the absence of sulphonylureas. 
A,., C indicate P < 0.05, 0.01, < 0.005, respectively, for ffects of the 
sulphonylureas, ss indicates non-significant (P = 0.34). 
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Fig. 1. Effects of tolbutamide and glibenclamide on microsomal ma- 
lonyl-CoA-sensitive CAT activity. Values are means + S.E.M. from 3 
separate preparations in each case. e, ©; malonyl-CoA-sensitive CAT 
in microsomal membrane r sidues depleted of malonyl-CoA-insensitive 
CAT by freezing/thawing. -,  ~; malonyl-CoA-sensitive CAT after solu- 
bilization and partial purification by gel-filtration. A, zx; partially-puri- 
fied malonyl-CoA-sensitive CAT after reconstitution into L-e-lecithin 
liposomes. Closed symbols, [carnitine] = 0.1 mM; open symbols, [car- 
nitine] = 2 mM. 
whereas glibenclamide was 5 to 10 times less effective as an 
inhibitor of the malonyl-CoA-insensitive enzyme (it was not 
possible to test concentrations of glibenclarnide in excess of 200 
/,tM because of its limited solubility). 
The effects of these two sulphonylurea drugs noted here have 
some similarities and some differences from their effects on the 
mitochondrial CATs shown by [10]. We found the concentra- 
tion of tolbutamide that produced 50% inhibition of the ma- 
lonyl-CoA-sensitive enzyme to be 70 to 150 times greater (de- 
pending on assay conditions) than the concentration of gliben- 
clamide needed for an equivalent degree of inhibition. In 
broadly similar experiments Cook [10] noted that glibenclamide 
was 35 times more potent than tolbutamide in inhibiting the 
mitochondrial malonyl-CoA-sensitive CAT (it should be noted 
that the bovine albumin in the assays will bind both drugs and 
that glibenclamide binds more tightly than tolbutamide [16]). 
When carnitine concentration was varied the effect of gliben- 
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Fig. 2. Comparison of the effects of tolbutamide and glibenclamide on
solubilized, partially purified preparations of microsomal malonyl- 
CoA-sensitive and malonyl-CoA-insensitive carnitine acyltransferase 
activities. Values are means + S.E.M. from 3 separate preparations in 
each case. All CAT assays contained 2 mM mcarnitine, m, m, with 
glibenclamide; o, e, with tolbutamide. Open symbols, malonyl-CoA- 
sensitive CAT; closed symbols, malonyl-CoA-insensitive CAT. 
clamide on the microsomal malonyl-CoA-sensitive CAT was 
non-competitive but was uncompetitive with the mitochondrial 
malonyl- CoA-sensitive CAT [10]. The observation (Fig. 2) that 
the two microsomal CATs clearly differ from each other in their 
sensitivity to glibenclamide reinforces arguments presented 
elsewhere [5,6] that these are different enzymes. 
The sulphonylurea drugs are widely used as adjuncts to 
dietary measures in the treatment of non-insulin-dependent 
diabetes by inhibiting B cell KATP channels following interac- 
tion with the recently cloned sulphonylurea receptor [17]. It 
may be speculated that CATs might have some similarity to the 
sulphonylurea receptor in the molecular motif(s) involved in the 
recognition of these drugs. Since the physiological role of the 
microsomal CATs is not yet known it is not possible to tell 
whether any of the various documented extrapancreatic effects 
of the sulphonylureas could result from interactions with mi- 
crosomal CATs. We are however struck by the facts that 5 mM 
tolbutamide inhibited VLDL secretion by rat hepatocytes by
75% [8] and (at physiological carnitine concentrations) al o 
inhibited the liver microsomal malonyl-CoA-sensitive CAT by 
75% (Fig. 1). 
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